Early data suggests the variant can also get around some of the immunity from vaccines, though they still appear to protect against serious illness and death.
The treatment, co-developed by GSK, gained approval from the U.K’s medicines regulator after a clinical trial showed a single dose slashed the risk of hospitalisation and death by 79% in high-risk adults with symptomatic infection.
The discovery highlights the uncertainty surrounding the origins of the new variant and suggests it was circulating long before being reported by South African researchers last week.